Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context

• Main Authors: Luis A. Rodriguez (Author), Holly Finertie (Author), Romain S. Neugebauer (Author), Bennett Gosiker (Author), Tainayah W. Thomas (Author), Andrew J. Karter (Author), Lisa K. Gilliam (Author), Caryn Oshiro (Author), Jaejin An (Author), Gregg Simonson (Author), Andrea E. Cassidy-Bushrow (Author), Sarah Dombrowski (Author), Margaret Nolan (Author), Patrick J. O'Connor (Author), Julie A. Schmittdiel (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) improve cardiorenal outcomes in patients with type 2 diabetes. Equitable use of SGLT2i and GLP-1 RA has the potential to reduce racial and ethnic health disparities. We ev...